Actions in Peru

RedGE: Why a compulsory license for the antiretroviral atazanavir is important in Peru (en español)

Peruvian court: Ministry of Health must answer compulsory license request


"In Peru, we have obtained one of the best prices in the region for lopinavir + ritonavir, through the availability of generics and competitive bidding.  But this situation could be changed by new patent applications.  The global campaign enables us to join forces to prevent patent-based monopolies, avoiding catastrophic effects for access to antiretroviral medicines."

-- Javier Llamoza, Health Action International Latin America-Carribean 

Peru benefits from generic competition in the market for lopinavir + ritonavir, and has achieved comparatively low prices of $396 per patient per year. While this has enabled the government to provide treatment to over 3,000 patients a year, there is concern that Abbott is seeking a monopoly on lopinavir + ritonavir, as it has registered several patent applications claiming some relation to the medicine.

Health Action International Latin America and PROSA sent a letter to Abbott and the Ministry of Health expressing their concern and asking Abbott to retract its patent applications. Activists also participated in a demonstration before the Ministry of Health.

See the letter to Abbott Laboratories here (in Spanish)

Demonstration for the global day of action (11/10/11)



Return to the Kaletra Campaign Homepage

Copyright © 2016 Public Citizen. Some rights reserved. Non-commercial use of text and images in which Public Citizen holds the copyright is permitted, with attribution, under the terms and conditions of a Creative Commons License. This Web site is shared by Public Citizen Inc. and Public Citizen Foundation. Learn More about the distinction between these two components of Public Citizen.

Public Citizen, Inc. and Public Citizen Foundation


Together, two separate corporate entities called Public Citizen, Inc. and Public Citizen Foundation, Inc., form Public Citizen. Both entities are part of the same overall organization, and this Web site refers to the two organizations collectively as Public Citizen.

Although the work of the two components overlaps, some activities are done by one component and not the other. The primary distinction is with respect to lobbying activity. Public Citizen, Inc., an IRS § 501(c)(4) entity, lobbies Congress to advance Public Citizen’s mission of protecting public health and safety, advancing government transparency, and urging corporate accountability. Public Citizen Foundation, however, is an IRS § 501(c)(3) organization. Accordingly, its ability to engage in lobbying is limited by federal law, but it may receive donations that are tax-deductible by the contributor. Public Citizen Inc. does most of the lobbying activity discussed on the Public Citizen Web site. Public Citizen Foundation performs most of the litigation and education activities discussed on the Web site.

You may make a contribution to Public Citizen, Inc., Public Citizen Foundation, or both. Contributions to both organizations are used to support our public interest work. However, each Public Citizen component will use only the funds contributed directly to it to carry out the activities it conducts as part of Public Citizen’s mission. Only gifts to the Foundation are tax-deductible. Individuals who want to join Public Citizen should make a contribution to Public Citizen, Inc., which will not be tax deductible.


To become a member of Public Citizen, click here.
To become a member and make an additional tax-deductible donation to Public Citizen Foundation, click here.